Reduced alcohol intake and reward associated with impaired endocannabinoid signaling in mice with a deletion of the glutamate transporter GLAST
- PMID: 22342743
- PMCID: PMC3372600
- DOI: 10.1016/j.neuropharm.2012.01.027
Reduced alcohol intake and reward associated with impaired endocannabinoid signaling in mice with a deletion of the glutamate transporter GLAST
Abstract
A hyperglutamatergic state has been hypothesized to drive escalation of alcohol intake. This hypothesis predicts that an impairment of glutamate clearance through inactivation of the astrocytic glutamate transporter, GLAST (EAAT1), will result in escalation of alcohol consumption. Here, we used mice with a deletion of GLAST to test this prediction. WT and GLAST KO mice were tested for alcohol consumption using two-bottle free-choice drinking. Alcohol reward was evaluated using conditioned place preference (CPP). Sensitivity to depressant alcohol effects was tested using the accelerating rotarod, alcohol-induced hypothermia, and loss of righting reflex. Extracellular glutamate was measured using microdialysis, and striatal slice electrophysiology was carried out to examine plasticity of the cortico-striatal pathway as a model system in which adaptations to the constitutive GLAST deletion can be studied. Contrary to our hypothesis, GLAST KO mice showed markedly decreased alcohol consumption, and lacked CPP for alcohol, despite a higher locomotor response to this drug. Alcohol-induced ataxia, hypothermia, and sedation were unaffected. In striatal slices from GLAST KO mice, long-term depression (LTD) induced by high frequency stimulation, or by post-synaptic depolarization combined with the l-type calcium channel activator FPL 64176 was absent. In contrast, normal synaptic depression was observed after application of the cannabinoid 1 (CB1) receptor agonist WIN55,212-2. Constitutive deletion of GLAST unexpectedly results in markedly reduced alcohol consumption and preference, associated with markedly reduced alcohol reward. Endocannabinoid signaling appears to be down-regulated upstream of the CB1 receptor as a result of the GLAST deletion, and is a candidate mechanism behind the reduction of alcohol reward observed.
Published by Elsevier Ltd.
Figures




Similar articles
-
Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors.Behav Brain Res. 2005 Nov 7;164(2):206-13. doi: 10.1016/j.bbr.2005.06.021. Behav Brain Res. 2005. PMID: 16140402
-
Knockout of alpha 5 nicotinic acetylcholine receptors subunit alters ethanol-mediated behavioral effects and reward in mice.Neuropharmacology. 2018 Aug;138:341-348. doi: 10.1016/j.neuropharm.2018.06.031. Epub 2018 Jun 23. Neuropharmacology. 2018. PMID: 29944862 Free PMC article.
-
Decreased ethanol preference and consumption in dopamine transporter female knock-out mice.Alcohol Clin Exp Res. 2002 Jun;26(6):758-64. Alcohol Clin Exp Res. 2002. PMID: 12068242
-
The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.Neuropharmacology. 2019 Dec 15;161:107559. doi: 10.1016/j.neuropharm.2019.03.002. Epub 2019 Mar 6. Neuropharmacology. 2019. PMID: 30851309 Free PMC article. Review.
-
GLAST But Not Least--Distribution, Function, Genetics and Epigenetics of L-Glutamate Transport in Brain--Focus on GLAST/EAAT1.Neurochem Res. 2015 Dec;40(12):2461-72. doi: 10.1007/s11064-015-1605-2. Epub 2015 May 14. Neurochem Res. 2015. PMID: 25972039 Review.
Cited by
-
Roles for the endocannabinoid system in ethanol-motivated behavior.Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:330-9. doi: 10.1016/j.pnpbp.2015.06.011. Epub 2015 Jun 26. Prog Neuropsychopharmacol Biol Psychiatry. 2016. PMID: 26123153 Free PMC article. Review.
-
Astrocyte regulation of synaptic signaling in psychiatric disorders.Neuropsychopharmacology. 2023 Jan;48(1):21-36. doi: 10.1038/s41386-022-01338-w. Epub 2022 May 16. Neuropsychopharmacology. 2023. PMID: 35577914 Free PMC article. Review.
-
Modeling escalation of drug intake to identify molecular targets for treating substance use disorders: A slippery slope upward.Neurosci Biobehav Rev. 2025 Jul;174:106175. doi: 10.1016/j.neubiorev.2025.106175. Epub 2025 Apr 23. Neurosci Biobehav Rev. 2025. PMID: 40280289 Review.
-
Distinct functions of endogenous cannabinoid system in alcohol abuse disorders.Br J Pharmacol. 2019 Sep;176(17):3085-3109. doi: 10.1111/bph.14780. Epub 2019 Jul 29. Br J Pharmacol. 2019. PMID: 31265740 Free PMC article. Review.
-
Astroglia in the Vulnerability and Maintenance of Alcohol Use Disorders.Adv Neurobiol. 2021;26:255-279. doi: 10.1007/978-3-030-77375-5_11. Adv Neurobiol. 2021. PMID: 34888838
References
-
- Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99:811–828. - PubMed
-
- Boyce Rustay JM, Wiedholz LM, Millstein RA, Carroll J, Murphy DL, Daws LC, Holmes A. Ethanol Related Behaviors in Serotonin Transporter Knockout Mice. Alcoholism: Clinical and Experimental Research. 2006;30:1957–1965. - PubMed
-
- Boyce-Rustay JM, Cunningham CL. The Role of NMDA Receptor Binding Sites in Ethanol Place Conditioning. Behavioral Neuroscience. 2004;118:822. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials